ライフサイエンスコーパス: pooled odds ratio

1 sis, and biomarkers were ranked according to pooled odds ratio.

2 Random and fixed models were used to achieve pooled odds ratios.

3 62R was not associated with type 2 diabetes (pooled odds ratio 0.97 [95% CI 0.88-1.08], P = 0.63).

4 were just as likely to accept HBT as women (pooled odds ratio = 0.84; 95% CI: 0.56-1.26) (tau(2) = 0

5 reduced the incidence of fungal infections (pooled odds ratio, 0.44; 95% confidence interval, 0.27-0

6 s were significant only for EBV-positive HL (pooled odds ratio, 0.56; 95% confidence interval, 0.35 t

7 ressive symptomatology after 6 to 12 months (pooled odds ratio, 0.60 [95% CI, 0.50-0.73]; reported in

8 1 year (78 [53%] of 147 vs 74 [51%] of 145; pooled odds ratio 1.12 [95% CI 0.70-1.79]; I(2)=0%).

9 -cohorts decreased the association slightly (pooled odds ratio 1.18, 95% confidence interval 0.98-1.3

10 disease in the Danish and Norwegian cohorts (pooled odds ratio 1.26, 95% confidence interval 1.16-1.3

11 ers who had the symptom under investigation (pooled odds ratio = 1.61, 95% confidence interval: 1.36,

12 moderately increased risk for spina bifida (pooled odds ratio = 1.8; 95% confidence interval: 1.4, 2

13 es within 1 year of intervention completion (pooled odds ratio, 1.03 [95% CI, 0.84-1.27]).

14 nt between screened male and female infants (pooled odds ratio, 1.04 [95% CI, 0.91-1.18]; P = .67).

15 with an increased risk of childhood asthma (pooled odds ratio, 1.34 [95% CI, 1.15-1.57], 1.32 [95% C

16 2.4% and in chronic kidney disease was 2.7%; pooled odds ratio, 1.6 (95% confidence interval, 1.3-1.8

17 r married counterparts across all countries (pooled odds ratio, 1.86; 95% confidence interval (CI), 1

18 05; P < .001); the benefit remained similar (pooled odds ratio, 1.96) when GIMEMA MM-BO2005 data were

19 were an independent predictor of death; the pooled odds ratio (12 studies) was 1.7 (95% confidence i

20 own to be significantly associated with IPV (pooled odds ratio 2.97, 95% CI 2.39 to 3.69).

21 y also appears to be a moderate risk factor (pooled odds ratio = 2.0; 95% confidence interval: 1.5, 2

22 compared with similar patients without VAP (pooled odds ratio, 2.03; 95% confidence interval, 1.16-3

23 s 53% and in chronic kidney disease was 73%; pooled odds ratio, 2.7 (95% confidence interval, 2.1-3.4

24 ed the risk for ACT; namely ABCC2 rs8187710 (pooled odds ratio: 2.20; 95% CI: 1.36-3.54), CYBA rs4673

25 reduced recurrence risk compared to sutures (pooled odds ratio: 2.46; 95% CI: 1.06-5.69; 27 P = .0352

26 than those below the threshold value (36%) (pooled odds ratio, 3.3; 95% confidence interval, 1.7-6.3

27 ose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval,

28 The pooled odds ratio (95% confidence interval) for atrial f

29 andida albicans was associated with CE, with pooled odds ratios (95% CI) of 6.92 (3.58-13.36) and 3.0

30 Pooled odds ratios, according to HCC surveillance status

31 In the absence of HR, pooled odds ratios analysis was conducted for secondary

32 Pooled odds ratios and 95% CI were calculated by random-

33 Pooled odds ratios and 95% confidence intervals were com

34 Pooled odds ratios and 95% confidence intervals were est

35 simulation with Gibbs sampling, calculating pooled odds ratios and associated 95% confidence interva

36 Pooled odds ratios and risk ratios were calculated using

37 The pooled odds ratio assessing risk of mortality for patien

38 ndom-effects model was used to calculate the pooled odds ratios based on the results from the heterog

39 odel was used to pool the data and calculate pooled odds ratios (endovascular vs open surgical repair

40 The pooled odds ratio estimate using 18 CRP genetic instrume

41 Pooled odds ratio for cardiotoxicity was 1.38 (95% CI, 1

42 PCSK9 LOF variants were associated with a pooled odds ratio for coronary heart disease of 0.51 (95

43 The pooled odds ratio for cross-sectional studies was 1.60 (

44 The pooled odds ratio for developing acute respiratory distr

45 antibiotics and the risk of celiac disease (pooled odds ratio for each additional dispensed antibiot

46 evalence was 11.8% (95% CI 11.6-12.0) with a pooled odds ratio for HIV infection of 13.5 (95% CI 10.0

47 In subgroup analysis, the pooled odds ratio for ICU mortality between the greater

48 The pooled odds ratio for malignancy was 3.3 (95% confidence

49 Compared with noncurrent users, the adjusted pooled odds ratio for MI in current OC users was 0.94 (9

50 Compared with never users, the adjusted pooled odds ratio for MI was 0.56 (0.21, 1.49) in curren

51 y department triage (< 3 hr reference) had a pooled odds ratio for mortality of 1.16 (0.92-1.46; p =

52 s/shock recognition (< 1 hr reference) had a pooled odds ratio for mortality of 1.46 (0.89-2.40; p =

53 The before-after tele-ICU implementation pooled odds ratio for overall ICU mortality was 0.75 (95

54 for ever vs never e-cigarette users, and the pooled odds ratio for past 30-day cigarette smoking at f

55 The pooled odds ratio for physician-diagnosed sciatica was 1

56 In a conventional meta-analysis, the pooled odds ratio for sensitisation was estimated as 0.2

57 After adjusting for these, the pooled odds ratio for sensitisation was estimated as 0.3

58 oral risk factors for cigarette smoking, the pooled odds ratio for subsequent cigarette smoking initi

59 For each biomarker, pooled odds ratios for clinical outcome were calculated

60 There was no increased mortality in the pooled odds ratios for each hourly delay from less than

61 Pooled odds ratios for ever use among 18 heterogeneous s

62 For the cross-sectional studies, the pooled odds ratio from the random-effects model was 1.18

63 ith paired data 2.57 (95% CI, 1.11-5.96) and pooled odds ratios from studies with independent data wa

64 Effects were summarized as pooled odds ratios in a random-effects model.

65 With 500 accumulated patients, the pooled odds ratio may change by 0.6- to 1.7-fold in the

66 The pooled odds ratios, mean differences, and corresponding

67 resent in more than one study, we calculated pooled odds ratios (meta-analysis).

68 The pooled odds ratio (nine studies) for developing an infec

69 days following critical care admission, with pooled odds ratio of 1.13 (95% CIs, 1.05-1.22).

70 emic colitis among patient with IBS with the pooled odds ratio of 2.50 (95% CI, 2.00-3.14; I(2) 57%).

71 The pooled odds ratio of being an infected contact in childr

72 ; P < .001; n = 14 067; I2 = 50.8%), and the pooled odds ratio of depression in those with vs without

73 The pooled odds ratio of subclinical PTC in women compared w

74 ary analysis, which included 11 studies, the pooled odds ratio of UTI among non-Black children was 2.

75 g random-effects meta-analyses, we estimated pooled odds ratios of the association of breastfeeding w

76 Whenever possible, a meta-analysis generated pooled odds ratios or mean difference.

77 with a significantly reduced odds of atopy (pooled odds ratio (OR) 0.82; 95% confidence interval (CI

78 was positively associated with incident T2D [pooled odds ratio (OR) 3.59 (95% CI: 1.49, 8.64, ptrend

79 oking during pregnancy and ASD in offspring (pooled odds ratio (OR) = 1.16, 95% CI: 0.97-1.40).

80 Both overweight (pooled odds ratio (OR) = 1.23, 95% confidence interval (

81 s and random-effects models to calculate the pooled odds ratio (OR) and 95% confidence interval (CI)

82 with higher risk of CHD in offspring, with a pooled odds ratio (OR) and 95% confidence interval (CI)

83 in the intervention group, translating to a pooled odds ratio (OR) for incidence of cutaneous advers

84 The pooled odds ratio (OR) for mortality risk in HAV superin

85 For all cancer combined, the pooled odds ratio (OR) for mortality was 2.32 (95% confi

86 iance weighted method was used to estimate a pooled odds ratio (OR) for the effect of a 5-kg/m2 highe

87 e, 36.8 [13.8] years; 258 [59.2%] male), the pooled odds ratio (OR) for the primary, 30-day composite

88 h decreased risk of colorectal cancer with a pooled odds ratio (OR) of 0.80 (95% confidence interval

89 d risk of CRC with exposure to oral BPs with pooled odds ratio (OR) of 0.87 (95% CI, 0.78 to 0.97).

90 ted to obstructive sleep apnea (OSA), with a pooled odds ratio (OR) of 3.66 (95% confidence interval

91 Summary estimates of pooled odds ratio (OR) of COVID-19-related AKI depending

92 Random-effects estimate of the pooled odds ratio (OR) of each outcome were generated wi

93 The pooled odds ratio (OR) of long COVID in those vaccinated

94 The pooled odds ratio (OR) was 1.46 (95% confidence interval

95 The pooled odds ratio (OR) was calculated to be 3.83 (95% CI

96 Pooled odds ratio (OR) was calculated using a fixed- or

97 g a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI

98 We then computed a pooled odds ratio (OR) with a 95% confidence interval an

99 fish consumption and risk of gastric cancer (pooled odds ratios (OR) = 0.99; 95% confidence interval

100 We estimated pooled odds ratios (OR) and 95% confidence intervals (CI

101 tio meta-analyses were performed to generate pooled odds ratios (OR) and 95% intrinsic confidence int

102 Random-effects models pooled odds ratios (OR) and mean differences (MD); PROMs

103 The pooled odds ratios (OR) and the 95% confidence intervals

104 Pooled odds ratios (OR) were obtained using a random eff

105 We calculated pooled odds ratios (OR), pooled risk ratios (RR), and 95

106 ated with reduced risk of colorectal cancer (pooled odds ratio [OR] 0.62, 95% CI 0.58-0.67, p(sig)<0.

107 0.85%) of 27 093 women in the placebo group (pooled odds ratio [OR] 0.77 [95% CI 0.63-0.93]; p=0.008)

108 tion to aspirin reduced death due to cancer (pooled odds ratio [OR] 0.79, 95% CI 0.68-0.92, p=0.003).

109 of grade 1 and higher kidney adverse events (pooled odds ratio [OR] 1.49, 95% CI 1.22-1.81; I(2)=25%)

110 to be admitted as nonpsychiatric inpatients (pooled odds ratio [OR] = 1.84, 95% confidence interval [

111 and 5-year mortality versus absence of CSPH (pooled odds ratio [OR] for 3-year mortality: 2.09; 95% c

112 he 1) association of M. genitalium with PID (pooled odds ratio [OR]) and 2) proportion of PID cases w

113 enotype was associated with reduced PD risk (pooled odds ratio [OR], 0.7; 95% confidence interval [CI

114 as associated with higher risk of psoriasis (pooled odds ratio [OR], 1.10; 95% CI, 1.05-1.15; P < .00

115 s associated with 11% increased odds of XFS (pooled odds ratio [OR], 1.11; 95% CI, 1.05-1.17; P < .00

116 ssociated with increased risk of cervicitis (pooled odds ratio [OR], 1.66 [95% confidence interval {C

117 iated with improved hand hygiene compliance (pooled odds ratio [OR], 1.82; 95% confidence interval [C

118 viduals had increased risk of schizophrenia (pooled odds ratio [OR], 2.07; 95% CI, 1.64-2.61) and PSs

119 men with schizophrenia and other psychoses (pooled odds ratio [OR], 4.5; 95% CI, 3.6-5.6) with subst

120 phically defined cases and control subjects (pooled odds ratio [OR]: 1.31, 95% confidence interval [C

121 were 76% more likely to be overweight/obese (pooled odds ratio [OR]: 1.76; 95% confidence interval [C

122 he risk of right bundle branch block (RBBB) (pooled odds ratio [OR]: 56.3; 95% CI: 11.6 to 273.9) alo

123 Pooled odds ratios (ORs) and 95% CIs were calculated for

124 Pooled odds ratios (ORs) and 95% CIs were calculated usi

125 Pooled odds ratios (ORs) and 95% confidence intervals (C

126 Random-effects models estimated pooled odds ratios (ORs) and 95% confidence intervals (C

127 Pooled odds ratios (ORs) and 95% confidence intervals (C

128 Random-effects meta-analysis obtained pooled odds ratios (ORs) and 95% confidence intervals (C

129 Pooled odds ratios (ORs) and 95% confidence intervals (C

130 Random effects model meta-analysis obtained pooled odds ratios (ORs) and 95% confidence intervals (C

131 ects meta-analysis was conducted to estimate pooled odds ratios (ORs) and 95% confidence intervals.

132 ertainty due to between-study variation, the pooled odds ratios (ORs) and 95% credible intervals (CrI

133 Pooled odds ratios (ORs) and corresponding 95% confidenc

134 Random effects models were used to calculate pooled odds ratios (ORs) and investigate heterogeneity b

135 nian-Laird random-effects model to calculate pooled odds ratios (ORs) and mean differences between wo

136 s with DerSimonian-Laird method to calculate pooled odds ratios (ORs) and standardized mean differenc

137 We calculated pooled odds ratios (ORs) and their 95% CIs using random-

138 Pooled odds ratios (ORs) and their 95% confidence interv

139 Data are reported as pooled odds ratios (ORs) by use of the generic inverse v

140 effects meta-analysis was used to calculate pooled odds ratios (ORs) for adverse childhood health ou

141 We estimated pooled odds ratios (ORs) for infection using random-effe

142 Random effects models were used to estimate pooled odds ratios (ORs) for outcomes obtained from cros

143 We calculated random-effects pooled odds ratios (ORs) for the association of suicide

144 f genotype by calculating study specific and pooled odds ratios (ORs) in meta-analyses, and assessed

145 We used random-effects models to calculate pooled odds ratios (ORs) of cancer risk for those with t

146 Pooled odds ratios (ORs) of inhibitor development for di

147 s significantly improved over time, with the pooled odds ratios (ORs) of surviving per 10-year increa

148 Pooled odds ratios (ORs) or standardized mean difference

149 Pooled odds ratios (ORs) or the mean difference (MD) wit

150 intensive care unit admission) by estimating pooled odds ratios (ORs) through a two-stage meta-analys

151 We calculated pooled odds ratios (ORs) using a random-effects model.

152 rived measures of association and calculated pooled odds ratios (ORs) using inverse-variance weighted

153 Pooled odds ratios (ORs) were estimated by either fixed

154 Pooled odds ratios (ORs) were estimated using the DerSim

155 Pooled odds ratios (ORs) with 95% CI were calculated usi

156 We calculated pooled odds ratios (ORs) with 95% CIs using random-effec

157 dom effects model were performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (

158 Pooled odds ratios (ORs) with 95% confidence intervals (

159 Pooled odds ratios (ORs) with corresponding confidence i

160 Overall and stratified pooled odds ratios (ORs) with their 95% CIs were obtaine

161 Data Extraction and Synthesis: Pooled odds ratios (ORs), 95% CIs, and P values were est

162 pooled standardised mortality ratios (SMRs), pooled odds ratios (ORs), and pooled risk ratios (RRs) o

163 Pooled odds ratios (ORs), mean differences (MD), and 95%

164 rmed using a fixed-effects model to estimate pooled odds ratios (ORs).

165 cts meta-analyses were performed to estimate pooled odds ratios (ORs).

166 effects meta-analyses were used to generate pooled odds ratios (ORs).

167 The pooled odds ratio per 5-year increase in age at last bir

168 ssociated with inability to balance for 5 s (pooled odds ratio per minor allele = 0.90, 95% CI: 0.82-

169 iated with a higher risk of thromboembolism [pooled odds ratio (pOR) 2.04, 95% confidence interval (C

170 with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval

171 iated with PJP development: acute rejection (pooled odds ratio (pOR) = 2.35 (1.69, 3.26), study heter

172 ith an increased risk of preschool wheezing (pooled odds ratio [pOR], 1.34; 95% CI, 1.25-1.43) and sc

173 iated with PJP development: acute rejection (pooled odds ratio [pOR], 2.35; 95% confidence interval [

174 (HRs) was performed for mortality risk, and pooled odds ratios (PORs) were calculated for discrete v

175 Pooled odds ratios (pORs) with 95% CIs were used to calc

176 dom-effect models were used to calculate the pooled odds ratio, prediction intervals expressed the am

177 Pooled odds ratios regarding the association between myo

178 e estimated and subsequently combined into a pooled odds ratio using a random-effects model.

179 We estimated pooled odds ratios using random-effect regression models

180 to one study; with that study excluded, the pooled odds ratio was 0.73 (95% CI: 0.64, 0.84) (Phetero

181 exposure and depression (n = 5 studies), the pooled odds ratio was 1.102 per 10-mug/m3 PM2.5 increase

182 The pooled odds ratio was 1.15 (95% confidence interval, 0.7

183 A pooled odds ratio was calculated using a fixed-effects m

184 The pooled odds ratios were 0.78 (95% confidence interval: 0

185 The pooled odds ratios were 2.15 (95% CI=1.58, 2.94) and 2.0

186 ase-control and cross-sectional studies, the pooled odds ratios were 2.24 (95% confidence interval: 1

187 and females, among longitudinal studies, the pooled odds ratios were 2.68 (95% CI, 1.86-3.87; I2 = 99

188 Pooled odds ratios were calculated for factors associate

189 The pooled odds ratios were determined using meta-analytic t

190 based on the random effects model to produce pooled odds ratios with 95% confidence intervals.